Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing regulatory approvals of contrast media
3.2.1.2 Growth in radiological examinations
3.2.1.3 Surging incidence of chronic diseases
3.2.1.4 Increase in minimally invasive procedures
3.2.2 Industry pitfalls & challenges
3.2.2.1 Presence of stringent regulations and frequent product recalls
3.2.2.2 Allergic reactions and side-effects associated with contrast media
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Iodinated contrast media
5.3 Gadolinium-based contrast media
5.4 Microbubble contrast media
5.5 Barium-based contrast media
Chapter 6 Market Estimates and Forecast, By Form, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Liquid
6.3 Powder
6.4 Other forms
Chapter 7 Market Estimates and Forecast, By Modality, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 X-ray
7.3 Computed tomography (CT)
7.4 Magnetic resonance imaging (MRI)
7.5 Ultrasound
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Intravascular route
8.3 Oral route
8.4 Rectal route
8.5 Other routes of administration
Chapter 9 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Cardiovascular disease
9.3 Cancer
9.4 Gastrointestinal disorders
9.5 Musculoskeletal disorders
9.6 Neurological disorders
9.7 Nephrological disorders
Chapter 10 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Radiology
10.3 Interventional radiology
10.4 Interventional cardiology
Chapter 11 Market Estimates and Forecast, By End User, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 Hospitals, clinics, and ASCs
11.3 Diagnostic imaging center
Chapter 12 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
12.1 Key trends
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Spain
12.3.5 Italy
12.3.6 Netherlands
12.3.7 Rest of Europe
12.4 Asia Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 South Korea
12.4.6 Rest of Asia Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest of Latin America
12.6 Middle East and Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 UAE
12.6.4 Rest of Middle East and Africa
Chapter 13 Company Profiles
13.1 Bayer AG
13.2 Bracco S.p.A.
13.3 GE HealthCare
13.4 Guerbet LLC
13.5 iMAX Diagnostic Imaging Limited
13.6 J.B. Chemicals & Pharmaceuticals Ltd.
13.7 Jodas Expoim Pvt. Ltd.
13.8 Lantheus Holdings, Inc.
13.9 Livealth Biopharma Pvt. Ltd.
13.10 nanoPET Pharma GmbH
13.11 Senochemia Pharmazeutika
13.12 Spago Nanomedical AB
13.13 TAEJOON Pharmaceutical Co., Ltd.
13.14 Trivitron Healthcare
13.15 Unijules Life Sciences Ltd.
